Product news

Share this article:

Sciele Pharma expaned its alliance with Sanofi-Aventis with a new exclusive, three-year agreement to market Allegra orally disintegrating tablets (ODT) and Allegra oral suspension in the pediatric market in the US. Under terms of the deal, Sciele will be responsible for all sales and marketing programs associated with the products in the US and will share revenues on both Allegra OS and ODT. Sciele expects to launch Allegra ODT in March 2008 through its 100 pediatric sales representatives.

Hisamitsu Pharmaceutical Co. obtained FDA approval for its topical analgesic product, Salonpas pain relief patch code-named FS-67.The product contains methyl salicylate and l-menthol as active ingredients and will be marketed as an OTC topical pain-reliever under the names of Salonpas  pain relief patch and Salonpas arthritis pain by Hisamitsu America.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.